Pet Care Diabetes Drug Market: Size, Share, Trends & Forecast (2025–2030)
The market report presents a thorough analysis segmented by Product Type (Insulin Drugs, SGLT2 Inhibitors, Others); by End User (Vet Hospital Pharmacies, Retail Pharmacies, Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East & Africa).
Outlook
- The pet care diabetes drug market is estimated to be at USD 805.16 Mn in 2025 and is anticipated to reach USD 1,104.57 Mn in 2030.
- The pet care diabetes drug market is registering a CAGR of 6.53% during the forecast period 2025-2030.
- The pet care diabetes drugs market is expected to grow strongly as more people own pets and the prevalence of diabetes increases. Advances in treatments, technological advancements and increasing pet humanization will also fuel the growth of this market.
Request a free sample.
Ecosystem
- The participants in the global pet care diabetes drug industry are continuously developing their strategies to preserve a competitive advantage.
- These companies primarily use acquisitions, Research & Developments, partnerships, and technological launches.
- Several important entities in the pet care diabetes drug market include Merko Ehitus Group; Zoetis Inc.; Allison Medical Inc.; UltiMed, Inc.; Boehringer Ingelheim International GmbH; and others.
Ask for customization.
Findings
| Attributes | Values |
|---|---|
| Historical Period | 2019-2023 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Market Size (2025) | USD 805.16 Mn |
| Market Size (2030) | USD 1,104.57 Mn |
| Growth Rate | 6.53% CAGR from 2025 to 2030 |
| Key Segments | Product Type (Insulin Drugs, SGLT2 Inhibitors, Others); End User (Vet Hospital Pharmacies, Retail Pharmacies, Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East & Africa) |
| Key Vendors | Merko Ehitus Group; Zoetis Inc.; Allison Medical Inc.; UltiMed, Inc.; Boehringer Ingelheim International GmbH |
| Key Countries | The US; Canada; Mexico; Brazil; Argentina; Chile; China; India; Japan; The UK; Germany; France; UAE; Israel; South Africa |
| Largest Market | North America |
Get a free quote.
Trends
- Advanced Innovations in Veterinary Medicine: The advanced veterinary solutions are improving the management of diabetes in pets by providing more accurate and convenient methods. Long-acting insulin provides better control over the blood sugar levels and making pet care routines easier, even for the pets with complex needs. Smart glucose monitoring devices that feature wireless connectivity and real time data tracking allow pet owners to easily monitor their pet’s glucose levels, reducing the risk of complications. These devices help veterinarians make more informed decisions by providing comprehensive health data. This technology leads to better treatment compliance and enhances the overall experience for both pets and their owners in managing diabetes.
- Emergence of Personalized Pet Care Solutions: The management of diabetes in pets is revolutionized by embracing personalized treatment plans based on individual genetic predispositions and lifestyle factors to increase the care of pets. Tailoring treatment strategies to each pets unique needs allows the veterinarians to attain accurate glucose control and better results in overall health outcomes. Advancements in genetic testing and lifestyle assessments are allowing for early detection of diabetes risks so that proactive care and prevention can be pursued. It makes the treatment more effective and improves the pet’s quality of life because personalized pet care is specifically tailored to their individual needs.
- Innovation in Pet-Friendly Medications: Pet specific diabetes treatments are being developed to meet more the exclusive needs of diverse species, lowering the risk of adverse side effects and making delivery easier. Oral medications and other non-invasive approaches to insulin delivery are promising, offering less stressed options for pets and their owners. In 2023, the pharmaceutical company Elanco Animal Health introduced Bexacat (bexagliflozin tablets), the first oral medication specifically for the management of feline diabetes. This innovation provides the first product for diabetes medicines tailored exclusively for cats, making diabetes care much easier for pet owners to care for their pets. This is indicative of future developments that would focus on and evolve species-specific treatment modalities. Innovations like that would improve veterinary care by providing practical options for chronically affected pets.
Speak to analyst.
Catalysts
- Rise in Pet Ownership: The increase in global pet ownership, particularly during the pandemic, has led to a higher demand for pet healthcare services. As more households adopt dogs, cats and other pets, chronic conditions like diabetes in animals have become more common and noticeable. Veterinary clinics are witnessing an increasing number of diabetics, thereby increasing demand for necessary drugs like insulin, glucose monitoring devices and dietary solutions. This increased demand has pushed the veterinary services to expand into more innovative diabetes management tools to meet the growing demand.
- Increase in Pet Diabetes Cases: The growing incidence of diabetes in pets, largely due to lifestyle related factors like obesity, lack of physical exercise, and unhealthy diet, is significantly increasing the demand for pet diabetes care solutions. The shift has increased the demand for products like insulin therapies, glucose monitoring devices and dietary management products specifically designed for pets. The growing awareness of the associated health risks among pet owners encourages veterinary clinics and manufacturers to see a sharp rise in demand for advanced and preventive care options.
- Demand for Diabetes Care Driven by Pet Humanization : The growing concept of pets as part of the family has changed dramatically in the pet healthcare sector, forcing owners to seek quality care for their pets. This change has also resulted in a considerable demand for improved treatments for diabetes in pets that closely resemble treatments available for humans. Humanization has substantially increased the willingness to invest in advanced diabetes treatments, just like those exhibited in human healthcare. For instance, Zoetis launched Librela for dogs in 2023, providing the same level of human-grade pain management, and this represents the shift towards premium veterinary solutions. Similar to this, demand for specialized diabetes drugs, glucose monitors, and dietary solutions has erupted because owners are looking for specific treatments for their pets. This growth drives innovation and extends the market for advanced diabetes pet care products.
Inquire before buying.
Restraints
- High Cost of Diabetes Care for Pets: The high expenditure involved in the treatment of pet diabetes is a serious problem, which makes it very difficult for the owners of pets to be able to afford the necessary treatments. Quick accumulation of several costs, such as routine glucose monitoring, injections of insulin, special diets and frequent veterinary consultations, may render diabetes care unaffordable for households across the board. The financial burden often deters the pet owners from following consistent treatment, leading to poor health outcomes for such diabetic pets. Affordability of care remains the most significant barrier to the wide scale acceptance of comprehensive diabetes management plans for pets.
- Limited Veterinary Infrastructure: Poor veterinary infrastructure in rural and underprivileged areas creates a significant hindrance to effective care for pets with diabetes. Clinics in such areas are underequipped, have old machines and lack the expertise to diagnose and treat diabetes. Thus, patients are given late treatment or insufficient treatment, which enhances the risk of diseases among diabetic animals. In regions with little veterinary access, pet owners have to travel long distances to reach special care services, which adds logistical and financial burdens to the owners, hindering the market for pet care diabetes drugs market.
- Limited Availability of Pet Specific Diabetes Drugs: One of the significant challenges posed in managing pet diabetes is that of making medication available. Not every pet has been provided with the type of insulins or drugs that are needed for therapeutics or treatment. Thus, most sources direct the owners to use human insulins for their pets under certain conditions. Some of these treatments can be dangerous because they may require a different dose, have a lower effectiveness, or may cause side effects that will be different from those observed in pet animals. Using medication not specifically developed for pet animals in the treatment of diabetes complicates the management of the disease and hence worsens the stress for the owners.
Personalize this research.
Hotspot
Explore purchase options.
Table of Contents
| 1. Introduction 1.1. Research Methodology 1.2. Scope of the Study 2. Market Overview / Executive Summary 2.1. Global Pet Care Diabetes Drug Market (2019 – 2023) 2.2. Global Pet Care Diabetes Drug Market (2024 – 2030) 3. Market Segmentation 3.1. Global Pet Care Diabetes Drug Market by Product Type 3.1.1. Insulin Drugs 3.1.2. SGLT2 Inhibitors 3.1.3. Others 3.2. Global Pet Care Diabetes Drug Market by End User 3.2.1. Vet Hospital Pharmacies 3.2.2. Retail Pharmacies 3.2.3. Others 4. Regional Segmentation 4.1. North America 4.1.1. The US 4.1.2. Canada 4.1.3. Mexico 4.2. South America 4.2.1. Brazil 4.2.2. Argentina 4.2.3. Chile 4.2.4. Rest of South America 4.3. Asia Pacific 4.3.1. China 4.3.2. India 4.3.3. Japan 4.3.4. Rest of Asia Pacific 4.4. Europe 4.4.1. The UK 4.4.2. Germany 4.4.3. France 4.4.4. Rest of Europe 4.5. The Middle East & Africa 4.5.1. Israel 4.5.2. UAE 4.5.3. South Africa 4.5.4. Rest of the Middle East & Africa 5. Value Chain Analysis of the Global Pet Care Diabetes Drug Market 6. Porter Five Forces Analysis 6.1. Threats of New Entrants 6.2. Threats of Substitutes 6.3. Bargaining Power of Buyers 6.4. Bargaining Power of Suppliers 6.5. Competition in the Industry 7. Trends, Drivers and Challenges Analysis 7.1. Market Trends 7.1.1. Market Trend 1 7.1.2. Market Trend 2 7.1.3. Market Trend 3 7.2. Market Drivers 7.2.1. Market Driver 1 7.2.2. Market Driver 2 7.2.3. Market Driver 3 7.3. Market Challenges 7.3.1. Market Challenge 1 7.3.2. Market Challenge 2 7.3.3. Market Challenge 3 8. Opportunities Analysis 8.1. Market Opportunity 1 8.2. Market Opportunity 2 8.3. Market Opportunity 3 9. Competitive Landscape 9.1. Merko Ehitus Group 9.2. Zoetis Inc. 9.3. Allison Medical Inc. 9.4. UltiMed, Inc. 9.5. Boehringer Ingelheim International GmbH 9.6. Company 6 9.7. Company 7 9.8. Company 8 9.9. Company 9 9.10. Company 10 |
Know the research methodology.
Pet Care Diabetes Drug Market – FAQs
1. What is the current size of the pet care diabetes drug market?
Ans. In 2025, the pet care diabetes drug market size is USD 805.16 Mn.
2. Who are the major vendors in the pet care diabetes drug market?
Ans. The major vendors in the pet care diabetes drug market are Merko Ehitus Group; Zoetis Inc.; Allison Medical Inc.; UltiMed, Inc.; Boehringer Ingelheim International GmbH.
3. Which segments are covered under the pet care diabetes drug market segments analysis?
Ans. The pet care diabetes drug market report offers in-depth insights into Product Type, End User, and Geography.